Friday 15 May 2015

Ruthenium-Based Water Oxidation Catalyst



Ruthenium-Based Water Oxidation Catalyst

Non-innocent ligand frameworks for promoting multi-electron reactions
Read more




http://www.chemistryviews.org/details/ezine/7705501/Ruthenium-Based_Water_Oxidation_Catalyst.html

  • Author: Claire D'Andola
  • Published Date: 12 May 2015
  • Source / Publisher: Chemistry – A European Journal/Wiley-VCH
  • Copyright: Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim

Markus Kärkäs, Rong-Zhen Liao, Björn Åkermark, and co-workers, Stockholm University, Sweden, and Huazhong University of Science and Technology, Wuhan, China, provide an insight into this mechanistic process by using a dinuclear Ru-based WOC.













 Stockholm University, Sweden

    • Image result for Stockholm University, Sweden
  1. Map of stockholm university
Stockholm University
University in Stockholm, Sweden


 


 


 



Monday 11 May 2015

DRONEDARONE




DRONEDARONE

Image result for Sanofi-Aventis,

Dronedarone (development codename SR33589 and marketed as Multaq) is a drug by Sanofi-Aventis, mainly for the indication ofcardiac arrhythmias. It was approved by the FDA on July 2, 2009
N-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-1-benzofuran-5-yl]methanesulfonamide NMR spectra analysis, Chemical CAS NO. 141626-36-0 NMR spectral analysis, N-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-1-benzofuran-5-yl]methanesulfonamide H-NMR spectrum



N-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-1-benzofuran-5-yl]methanesulfonamide NMR spectra analysis, Chemical CAS NO. 141626-36-0 NMR spectral analysis, N-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-1-benzofuran-5-yl]methanesulfonamide C-NMR spectrum


  • Dronedarone (SR33589) is a benzofuran derivative that is a new potent drug in the treatment of arrhythmia. Chemically, dronedarone is similar to amiodarone, but it has no iodine, so it is less lipophilic than amiodarone. Dronedarone not only retains the curative effects of amiodarone, but also has no extracardiac adverse response of amiodarone. It is expected to become a drug that is more safe, tolerated better by patients, and one alternative of amiodarone for the treatment of arrhythmia.
  • [0003]
    Along with the faster moving social modernization process and the higher social pressure people bear, the number of patients with cardiovascular disease in our country is increasing. Cardiovascular disease is listed as one of the top ten causes of death. Therefore, the development of dronedarone will bring great economic benefit and social benefit. Dronedarone is represented as formula [I]:
    Figure imgb0001
  • [0004]
    US5223510A disclosed a process for preparing dronedarone as shown in scheme 1. In this patent, dronedarone is prepared by converting 2-butyl-5-nitrobenzofuran to 5-amino-2- butyl-3-(4-[3-(dibutylamino)propoxy]benzoyl)benzofuran (compound A) via acylation, hydrolysis, O-alkylation and reduction; then reacting the compound A with methanesulfonyl chloride in the presence of triethylamine as a catalyst to obtain acyl compound; and then purifying the acyl compound by column chromatography. Finally, dronedarone hydrochloride is obtained by treating dronedarone with hydrogen chloride-ether in ethyl acetate.
    Figure imgb0002
    Figure imgb0003
  • [0005]
    In this process, the compound A is reacted with methanesulfonyl chloride to easily obtain the undesired double methanesulfonyl compound (a compound of formula Ia), which requires a further purification of dronedarone by column chromatography. It is not very economic for industrial production. In addition, an additional salifying step of dronedarone hydrochloride is needed which costs more reaction equipment and reduces overall yield, and increases production costs at the same time.
    Figure imgb0004
  • [0006]
    Many processes for the acylation of amines have been reported.US 5,223,510A also disclosed that double methanesulfonyl compound IIa, not monomethyl sulfonyl compound (II), is obtained by reacting 5-amino-2-butyl-benzofuran in carbon tetrachloride with methanesulfonyl chloride in the presence of triethylamine as a catalyst. Compound IIa can be converted to compound II via deacylation with an additional deacylation step, which also increases the production cost, and is unfavorable for industrialized production. It is shown in scheme 2:
    Figure imgb0005
    Figure imgb0006
  • [0007]
    WO 03/048144A2 reported a process for preparing compound II by adjusting the proportion of compound II and compound IIa under different catalysts to an optimized condition (5<Pka<10) by using 2-butylbenzofuran-5-amine.
  • [0008]
    Subsequently, US2005049302 described a process for preparing compound II, not compound IIa, from 5-amino-2-butyl-benzofuran. In this process, compound II is reacted with compound III in the presence of tin tetrachloride (scheme 3) to obtain dronedarone with low yield and complicated operations, such as column chromatography etc., which is not suitable for industrial production.
    Figure imgb0007

 The process comprises reacting 5-amino-2-butyl-3-(4-[3-(dibutylamino)propoxy]benzoyl)benzofuran (compound A) with methanesulfonyl chloride to provide dronedarone hydrochloride; and then converting the dronedarone hydrochloride to highly pure dronedarone via treatment with an alkaline solution, or based on the need, converting to other pharmaceutically acceptable salts of dronedarone. It is shown in scheme 4:
Figure imgb0008




    Example 1Step 1) Preparation of crude dronedarone hydrochloride
  • [0036]
    In a 5L flask, 480 g compound A (1mol) and 1.7 L acetonitrile were added and heated to reflux to obtain a mixture. Then, 100 mL methanesulfonyl chloride (1.29mol)/800mL acetonitrile were added dropwise to the mixture within 25∼30min. The reaction was maintained at reflux for 8 h. Then, the reaction was naturally cooled to obtain a solid. The next day, the solid obtained was filtered and dried to obtain 530 g crude dronedarone hydrochloride. Yield: 89.2%, Purity of HPLC: 99.5%.
  • Step 2) Preparation of dronedarone hydrochloride
  • [0037]
    In a 5L flask, 530 g crude dronedarone hydrochloride, 3 L acetone and 100 mL water were added and heated to reflux for dissolving completely. The reaction mass was cooled for crystallization in an ice water bath under automatic stirring. About 30 minutes later, lots of solid was precipitated. The solid obtained was filtered and washed with acetone and dried to obtain 440 g targeted compound. Yield: 83%, mp:141.5∼143°C, Purity of HPLC: 99.8%, MS:[M+H]+m/e 557.50.
    Figure imgb0009
    Table 1. dronedarone hydrochloride 1H-NMR data and assignments
    Chemical shift (ppm)multiplicityThe number of protonsProton assignmentThe chemical shifts of the relevant hydrogen (ppm)
    0.799-0.829t3271.226-1.270
    0.908-0.937t622, 22'1.323-1.368
    1.226-1.270m2260.799-0.829, 1.647-1.738
    1.323-1.368m421, 21'0.908-0.937, 1.647-1.738
    1.647-1.738m620, 20', 251.226-1.270, 1.323-1.368, 2.801-2.831, 3.036-3.079
    2.230-2.262m2173.209-3.250, 4.207-4.231
    2.801-2.831t2241.647-1.738
    2.902s323
    3.036-3.079m419, 19'1.647-1.738, 11.0
    3.209-3.250m2182.230-2.262, 11.0
    4.207-4.231t2162.230-2.262
    7.100-7.117d212, 147.793-7.811
    7.240-7.262d167.613-7.631
    7.307-7.311s12
    7.613-7.631d157.240-7.262
    7.793-7.811d211, 157.100-7.117
    9.660s1NHDisappeared after exchange with D2O
    11.0br1HCl3.036-3.079, 3.209-3.250, Disappeared after exchange with D2O
Org. Process Res. Dev.201418 (1), pp 157–162
DOI: 10.1021/op400190b

Abstract Image
Six potential process related impurities were detected during the impurity profile study of an antiarrhythmic drug substance, Dronedarone (1). Simple high performance liquid chromatography and liquid chromatography–mass spectrometry methods were used for the detection of these process impurities. Based on the synthesis and spectral data (MS, IR, 1H NMR, 13C NMR, and DEPT), the structures of these impurities were characterized as 5-amino-3-[4-(3-di-n-butylaminopropoxy)benzoyl]-2-n-butylbenzofuran (impurity I); N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)benzofuran-5-yl)-N-(methylsulfonyl)methanesulfonamide (impurity II); N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)benzofuran-5-yl)-1-chloromethanesulfonamide (impurity III); N-{2-propyl-3-[4-(3-dibutylaminopropoxy)benzoyl]benzofuran-5-yl}methanesulfonamide (impurity IV); N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)benzofuran-5-yl)formamide (impurity V); and (2-butyl-5-((3-(dibutylamino)propyl)amino)benzofuran-3-yl)(4-(3-(dibutylamino)propoxy)phenyl)methanone (impurity VI). The synthesis and characterization of these impurities are discussed in detail.



Dronedarone
Dronedarone structure.svg
Systematic (IUPAC) name
N-(2-Butyl-3-(p-(3-(dibutylamino)propoxy)benzoyl)-
5-benzofuranyl)methanesulfonamide
Clinical data
Trade namesMultaq
AHFS/Drugs.commonograph
MedlinePlusa609034
Licence dataUS FDA:link
  • US: X (Contraindicated)
Oral
Pharmacokinetic data
Bioavailability15% (with a high-fat meal)[1]
Protein binding>98%
MetabolismExtensive hepatic (mainly by CYP3A)
Half-life13–19 hours
ExcretionFeces (84%), urine (~6%)
Identifiers
141626-36-0 
C01BD07
PubChemCID 208898
ChemSpider180996 Yes
UNIIJQZ1L091Y2 Yes
KEGGD02537 Yes
ChEBICHEBI:50659 Yes
ChEMBLCHEMBL184412 Yes
Chemical data
FormulaC31H44N2O5S
556.758 g/mol

Dronedarone synth.png



US5223510 †Jul 26, 1991Jun 29, 1993SanofiAlkylaminoalkyl derivatives of benzofuran, benzothiophene, indole and indolizine, process for their preparation and compositions containing them
AHMED KAMAL ET AL: 'BASE-FREE MONOSULFONYLATION OF AMINES USING TOSYL OR MESYL CHLORIDE IN WATER' TETRAHEDRON LETTERS vol. 49, no. 2, 13 November 2007, pages 348 - 353, XP022386883
2AKITO YASUHARA ET AL: 'SELECTIVE MONODESULFONYLATION OF N,N-DISULFONYLARYLAMINES WITH TETRABUTYLAMMONIUM FLUORIDE' CHEM. PHARM. BULL vol. 47, no. 6, June 1999, pages 809 - 812, XP003033477
3*KAMAL ET AL: "Base-free monosulfonylation of amines using tosyl or mesyl chloride in water", TETRAHEDRON LETTERS, PERGAMON, GB, vol. 49, no. 2, 13 November 2007 (2007-11-13), pages 348-353, XP022386883, ISSN: 0040-4039, DOI: 10.1016/J.TETLET.2007.11.044
4*No further relevant documents disclosed
5See also references of WO2011153923A1


.............. 


Île-de-France

Map of ile de france








Image result for ile de france
























Espace Congres Les Esselieres, Villejuif - Semgest Evénements - CRT Ile-de-France







...............